Topic Summary
New research is providing more evidence and understanding about the effectiveness and safety of tirzepatide versus semaglutide. Hear from A/Prof Samantha Hocking about this latest study and what it means for prescribing clinicians who are using these agents as part of their management of patients with obesity.
Featured Expert
A/Prof Samantha Hocking
Endocrinologist; Royal Prince Alfred Hospital; Clinical Academic at Charles Perkins Research Centre, University of Sydney; President, National Association of Clinical Obesity Services (NACOS)
Learning Objectives
- Compare the effectiveness and safety profiles of tirzepatide and semaglutide based on the latest research findings
- Interpret key insights from the study and understand their implications for clinical decision-making in obesity management
- Implement updated evidence to inform prescribing practices when using tirzepatide or semaglutide in patients with obesity
CPD and Accreditation
This activity is accredited with the RACGP and ACRRM for the following hours:
- 0.5 hours in the Educational Activities (EA)
- 0.5 hours Reviewing Performance (RP)
- 1 hour Measuring Outcomes (MO)
Disclosure Statement
Proudly supported by an independent educational grant from Lilly.
